🇺🇸 FDA

Intelligence Platform

Patents

Browse 302 pharma-relevant US patents (A61K/A61P) linked to tracked companies. Patent cliff and LOE intelligence for BD teams.

29,054 patents indexed
patent

US 12310929

Use of rasagiline for the treatment of restless legs syndrome

TEVA PHARMACEUTICAL INDUSTRIES, LTD. · Granted Tue May 27 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon May 22 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11472772

S1P3 antagonists

TEVA PHARMACEUTICAL INDUSTRIES, LTD. · Granted Tue Oct 18 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 13 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11135154

Medroxyprogesterone acetate injectable compositions and methods of use

TEVA PHARMACEUTICAL INDUSTRIES, LTD. · Granted Tue Oct 05 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 30 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10130621

Analogs of pridopidine, their preparation and use

TEVA PHARMACEUTICAL INDUSTRIES, LTD. · Granted Tue Nov 20 2018 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 15 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9951017

S1P3 antagonists

TEVA PHARMACEUTICAL INDUSTRIES, LTD. · Granted Tue Apr 24 2018 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 19 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9763993

Process for manufacturing glatiramer acetate product

TEVA PHARMACEUTICAL INDUSTRIES, LTD. · Granted Tue Sep 19 2017 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 14 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9702007

Genetic markers predictive of response to glatiramer acetate

TEVA PHARMACEUTICAL INDUSTRIES, LTD. · Granted Tue Jul 11 2017 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 06 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9687522

Methods of treating a subject afflicted with an autoimmune disease using predictive biomar

TEVA PHARMACEUTICAL INDUSTRIES, LTD. · Granted Tue Jun 27 2017 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 22 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9662322

Laquinimod for the treatment of relapsing-remitting multiple sclerosis (RRMS) patients wit

TEVA PHARMACEUTICAL INDUSTRIES, LTD. · Granted Tue May 30 2017 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon May 25 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9625473

Cytokine biomarkers as predictive biomarkers of clinical response for glatiramer acetate

TEVA PHARMACEUTICAL INDUSTRIES, LTD. · Granted Tue Apr 18 2017 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 13 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9617596

Biomarkers predictive for clinical response for glatiramer acetate

TEVA PHARMACEUTICAL INDUSTRIES, LTD. · Granted Tue Apr 11 2017 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 06 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9585878

Treatment of BDNF-related disorders using laquinimod

TEVA PHARMACEUTICAL INDUSTRIES, LTD. · Granted Tue Mar 07 2017 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 02 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9499868

Determination of single nucleotide polymorphisms useful to predict response for glatiramer

TEVA PHARMACEUTICAL INDUSTRIES, LTD. · Granted Tue Nov 22 2016 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 17 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9409662

Formulations of albu-BChE, preparation and uses thereof

TEVA PHARMACEUTICAL INDUSTRIES, LTD. · Granted Tue Aug 09 2016 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Aug 04 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9375403

Formulations of 6-mercaptopurine

TEVA PHARMACEUTICAL INDUSTRIES, LTD. · Granted Tue Jun 28 2016 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 23 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9346746

R(+)-N-formyl-propargyl-aminoindan

TEVA PHARMACEUTICAL INDUSTRIES, LTD. · Granted Tue May 24 2016 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon May 19 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9339469

R(+)-N-methyl-propargyl-aminoindan

TEVA PHARMACEUTICAL INDUSTRIES, LTD. · Granted Tue May 17 2016 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon May 12 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9340307

Stable laquinimod preparations

TEVA PHARMACEUTICAL INDUSTRIES, LTD. · Granted Tue May 17 2016 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon May 12 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9308182

Parenteral formulations of rasagiline

TEVA PHARMACEUTICAL INDUSTRIES, LTD. · Granted Tue Apr 12 2016 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 07 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9284276

N-ethyl-N-phenyl-1,2-dihydro-4,5-di-hydroxy-1-methyl-2-oxo-3-quinolinecarboxamide, prepara

TEVA PHARMACEUTICAL INDUSTRIES, LTD. · Granted Tue Mar 15 2016 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 10 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9233927

Crystals of laquinimod sodium and improved process for the manufacture thereof

TEVA PHARMACEUTICAL INDUSTRIES, LTD. · Granted Tue Jan 12 2016 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 07 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9186333

Process for preparing pharmaceutical compositions of fingolimod

TEVA PHARMACEUTICAL INDUSTRIES, LTD. · Granted Tue Nov 17 2015 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 12 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9180097

Formulations of 6-mercaptopurine

TEVA PHARMACEUTICAL INDUSTRIES, LTD. · Granted Tue Nov 10 2015 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 05 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9161935

Use of laquinimod for treating Crohn's disease patients who failed first-line anti-TNF the

TEVA PHARMACEUTICAL INDUSTRIES, LTD. · Granted Tue Oct 20 2015 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 15 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

granted